share_log

UBS Downgrades Royalty Pharma to Neutral, Announces $28 Price Target

UBS Downgrades Royalty Pharma to Neutral, Announces $28 Price Target

瑞銀將Royalty Pharma評級下調為中立,公佈28美元的目標價格。
Benzinga ·  06/03 11:50

UBS analyst Ashwani Verma downgrades Royalty Pharma (NASDAQ:RPRX) from Buy to Neutral and announces $28 price target.

瑞銀分析師Ashwani Verma將Royalty Pharma (NASDAQ:RPRX)的評級從買入下調至中立,並宣佈目標價爲28美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論